BioCentury
ARTICLE | Clinical News

Northera droxidopa: Completed Phase II enrollment

August 15, 2011 7:00 AM UTC

Chelsea completed enrollment of 120 patients in the double-blind, U.K. Phase II FMS201 trial. The 12-arm study is evaluating 200, 400 or 600 mg of oral droxidopa given 3 times daily; 25 or 50 mg carbi...